ORIC
HealthcareORIC Pharmaceuticals, Inc. · Biotechnology · $860M
What is ORIC Pharmaceuticals, Inc.?
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer therapies that overcome treatment resistance. Headquartered in South San Francisco, California, the company targets mechanisms that allow tumors to evade chemotherapy and immunotherapy.
ORIC Pharmaceuticals discovers and develops precision oncology medicines, concentrating on cancer resistance mechanisms. The company advances orally bioavailable small molecules and targeted inhibitors through clinical trials. Revenue is not yet generated from product sales — the company funds operations through capital raises and collaboration agreements, including partnerships with Voronoi Inc. and a license agreement with Mirati Therapeutics. Its pipeline targets specific genetic mutations and biological pathways that drive cancer progression and treatment resistance.
ORIC Pharmaceuticals was incorporated in 2014 and is based in South San Francisco, California.
- ORIC-533: oral CD73 inhibitor targeting chemotherapy and immunotherapy resistance
- ORIC-944: allosteric PRC2 inhibitor for prostate cancer
- ORIC-114: brain-penetrant EGFR/HER2 inhibitor targeting exon 20 insertion mutations
- Discovery-stage precision medicines targeting additional cancer resistance pathways
Is ORIC a Good Stock to Buy?
UQS Score rates ORIC as Poor overall, reflecting the early-stage nature and financial profile typical of pre-revenue clinical biotechs.
The Risk pillar stands out as the relative bright spot within ORIC's profile — an uncommon distinction for a small-cap clinical-stage company. This suggests the balance sheet carries a degree of near-term resilience, which matters when a company has no product revenue.
Quality, Moat, Growth, and Valuation all register as weak or elevated, consistent with a company that has yet to commercialize any product and faces a long, uncertain path to profitability.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ORIC pay dividends?
No — ORIC Pharmaceuticals, Inc. does not currently pay a dividend.
ORIC Pharmaceuticals does not pay a dividend. Clinical-stage biotechs at this point in their development cycle typically reinvest all available capital into research, clinical trials, and operations. Investors in ORIC are generally seeking potential long-term appreciation tied to pipeline milestones rather than income distributions.
When does ORIC report earnings?
ORIC Pharmaceuticals reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, ORIC's quarterly reports center on cash runway, operating expenses, and pipeline progress rather than sales or earnings growth. Investors typically focus on clinical trial updates and partnership developments as the key indicators of progress.
For the most recent quarter's results and pipeline updates, visit ORIC Pharmaceuticals' investor relations page directly.
ORIC Price History
-53.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in ORIC Pharmaceuticals, Inc.?
Based on ORIC Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ORIC Long-term Outlook
ORIC's fundamental outlook is shaped by its clinical pipeline timeline rather than near-term financial performance. With Growth and Quality both rated Weak, the path to meaningful revenue depends entirely on clinical trial outcomes and potential partnership or licensing activity. The Good Risk rating provides some buffer, but the Elevated Valuation label suggests the market may already be pricing in optimistic scenarios relative to where the pipeline currently stands.
Growth drivers
- Positive clinical trial data across ORIC-533, ORIC-944, or ORIC-114 programs
- Expanded collaboration agreements or licensing deals with larger pharmaceutical partners
- Growing clinical need for therapies targeting cancer treatment resistance mechanisms
Key risks
- Clinical trial failure or delays across any of the three lead programs
- Ongoing cash consumption with no product revenue to offset operating expenses
- Elevated valuation relative to current pipeline stage increases downside if milestones slip
ORIC vs Peers
ORIC operates in a competitive clinical-stage oncology space alongside other small-cap biotechs pursuing differentiated therapeutic approaches.
Aktis Oncology focuses on targeted radiopharmaceuticals for cancer, a distinct modality from ORIC's small-molecule oral inhibitor approach.
uniQure pursues gene therapy rather than small-molecule oncology, giving it a different risk and development profile compared to ORIC.
Geron has advanced a telomerase inhibitor into later-stage development for blood cancers, representing a more mature pipeline stage than ORIC's current programs.
Frequently Asked Questions
What does ORIC Pharmaceuticals do?
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company that develops cancer therapies designed to overcome treatment resistance. Its pipeline includes oral small molecules and targeted inhibitors aimed at specific genetic mutations and biological pathways. The company has no approved products and funds operations through capital markets and collaboration agreements.
Does ORIC pay dividends?
No, ORIC Pharmaceuticals does not pay a dividend. The company is pre-revenue and directs all capital toward clinical development and operations. Dividend payments are not typical for clinical-stage biotechs at this stage of development.
When does ORIC report earnings?
ORIC Pharmaceuticals reports on a quarterly cadence standard for US-listed companies. Because it is pre-revenue, reports focus on cash position and pipeline milestones rather than sales figures. Check ORIC's investor relations page for the most current schedule and results.
Is ORIC a good stock to buy?
UQS Score rates ORIC as Poor overall, driven by Weak ratings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. The relative strength is in the Risk pillar. Whether ORIC fits a portfolio depends on an investor's tolerance for clinical-stage biotech risk and pipeline conviction.
Is ORIC overvalued?
The UQS Valuation pillar for ORIC is rated Elevated, suggesting the current market price may reflect optimistic assumptions relative to the company's pre-revenue, clinical-stage position. Valuation for clinical biotechs is inherently speculative and tied to pipeline outcome probabilities.
How does ORIC compare to its competitors?
ORIC competes in the clinical-stage oncology space alongside companies like Aktis Oncology, uniQure, and Geron. Each pursues different therapeutic modalities — radiopharmaceuticals, gene therapy, and telomerase inhibition respectively. ORIC's differentiation lies in its focus on oral small molecules targeting cancer resistance mechanisms. Full UQS comparisons are available to Pro members.
What is ORIC's market cap bracket?
ORIC Pharmaceuticals is classified as a small-cap company. This places it in a segment of the market characterized by higher volatility, more limited liquidity, and greater sensitivity to clinical trial news compared to large- or mega-cap peers.
Who founded ORIC Pharmaceuticals?
ORIC Pharmaceuticals was incorporated in 2014. Founding and leadership history is publicly available through the company's official filings and investor relations materials for those seeking detailed background on the management team.
Is ORIC a long-term quality investment?
As a long-term quality indicator, ORIC's UQS profile currently rates Poor, with Weak scores across Quality, Moat, and Growth pillars. Long-term quality typically requires durable competitive advantages and financial strength — attributes that clinical-stage companies must still demonstrate through pipeline success and eventual commercialization.
What is the main competitive advantage of ORIC Pharmaceuticals?
ORIC's scientific focus on cancer treatment resistance is its core differentiator — a clinically meaningful problem with limited existing solutions. Its pipeline targets specific molecular mechanisms like CD73, PRC2, and EGFR exon 20 mutations. However, the UQS Moat pillar is currently rated Weak, reflecting that no commercial product yet validates this scientific approach.
What sector does ORIC belong to?
ORIC Pharmaceuticals operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals and precision oncology. Investors can explore other [Healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.
Unlock Full ORIC Pharmaceuticals Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare ORIC against clinical-stage oncology peers
- ✓Track pipeline-stage risk indicators in one dashboard
- ✓Get the full analyst-style quality profile for Pro members
Pro Analysis
ORIC — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 16.2 | 0.0 | 13.0 | 11.3 | 71.5 | 0.0 | -0.2 |
| Apr 22, 2026 | 16.4 | 0.0 | 13.0 | 11.3 | 72.8 | 0.0 | -0.6 |
| Apr 2, 2026 | 17.0 | 0.0 | 13.0 | 14.2 | 72.8 | 0.0 | — |
ORIC — Pillar Breakdown
Quality
— 0.0/100 (25%)ORIC Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 11.3/100 (20%)ORIC Pharmaceuticals, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 71.5/100 (15%)ORIC Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)ORIC Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)ORIC Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ORIC.
Score Composition
Financial Data
More Stock Analysis
How is the ORIC UQS Score Calculated?
The UQS (Unified Quality Score) for ORIC Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses ORIC Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether ORIC Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.